organovo 3d bioprinter 800x450

Organovo (NYSE: ONVO) announced today that they entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (NYSE: MRK).

The Agreement will give Merck access to Organovo’s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting PlatformTM, for use in drug development.